Trial Profile

Study of Efficacy of OXN PR, Compared to Oxy PR, for Reduction of Intensity of Opioid-induced Constipation Symptoms in patients Treated for Cancer or Non-cancer Pain: A Randomised, Double-blind, Controlled, Multicentre Study.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naloxone/oxycodone (Primary) ; Oxycodone
Indications Back pain; Cancer pain; Constipation; Musculoskeletal pain; Pain
Focus Registrational; Therapeutic Use
Sponsors Mundipharma International

04 Jul 2012 Napp Pharmaceutical Group added as associations as reported in the European Clinical Trials Database record.
15 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
07 Jun 2011 Planned end date (May 2012) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com